CD68-ET3-LV

DB32864InvestigationalCell transplant therapies

CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

Mechanism: Pharmacologically active on Coagulation factor VIII (F8)
Curator reviewed
Code names: CD68-ET3-LV

What you can answer from here — as of July 02, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of CD68-ET3-LV, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account